Australian and New Zealand Living Guideline cholesterol-lowering therapy for people with chronic kidney disease (CARI Guidelines): Reducing the evidence-practice gap
Files
(Published version)
Date
2024
Authors
Cashmore, B.
Tunnicliffe, D.J.
Palmer, S.
Blythen, L.
Boag, J.
Kostner, K.
Krishnasamy, R.
Lambert, K.
Miller, A.
Mullan, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Nephrology, 2024; 29(8):495-509
Statement of Responsibility
Brydee Cashmore, David J. Tunnicliffe, Suetonia Palmer, Llyod Blythen, Jane Boag, Karam Kostner, Rathika Krishnasamy, Kelly Lambert, Andrea Miller, Judy Mullan, Maira Patu, Richard K. S. Phoon, Liz Rix, Natasha Trompf, David W. Johnson, Robert Walker, on behalf of the CARI Guidelines Steering Committee
Conference Name
Abstract
Aim: People with chronic kidney disease experience high rates of cardiovascular disease. Cholesterol‐lowering therapy is a mainstay in the management but there is uncertainty in the treatment effects on patient‐important outcomes, such as fatigue and rhabdomyolysis. Here, we summarise the updated CARI Australian and New Zealand Living Guidelines on cholesterol‐lowering therapy in chronic kidney disease. Methods: We updated a Cochrane review and monitored newly published studies weekly to inform guideline development according to international standards. The Working Group included expertise from nephrology, cardiology, Indigenous Health, guideline development and people with lived experience of chronic kidney disease. Results: The guideline recommends people with chronic kidney disease (eGFR ≥15 mL/min/1.73 m2 ) and an absolute cardiovascular risk of 10% or higher should receive statin therapy (with or without ezetimibe) to reduce the risk of cardiovascular events and death (strong recommendation, moderate certainty evidence). The guidelines also recommends a lower absolute cardiovascular risk threshold (≥5%) for Aboriginal and Torres Strait Islander Peoples and Māori with chronic kidney disease to receive statin therapy (with or without ezetimibe) (strong recommendation, low certainty evidence). The evidence was actively surveyed from 2020–2023 and updated as required. No changes to guideline recommendations were made, with no new data on the balance and benefits of harms. Conclusions: The development of living guidelines was feasible and provided the opportunity to update recommendations to improve clinical decision‐making in real‐ time. Living guidelines provide the opportunity to transform chronic kidney disease guidelines.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2024 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.